Choonhakarn C, et al. - The aim of this trial was to illustrate the outcomes of the treatment dose reduction in desloratadine in patients with chronic spontaneous urticaria, via the urticarial activity score over 7 successive days. For obtaining remission, most patients required higher than the standard doses of this drug. Nonetheless, in order to avoid recurrence of the symptoms once the disease was controlled completely, maintenance of the same dosage was recommended for at least 8 weeks before the dose reduction.